BMO Capital says that in a in a “surprise announcement,” CytomX Therapeutics (CTMX) this morning announced it will provide an initial CX-904 Phase 1a dose escalation update when it reports Q1 results on May 8. CytomX had previously guided to CX-904 initial Phase 1a data in solid tumors in the second half of 2024, the analyst tells investors in a research note. The firm says the Phase 1a data is intended to inform a potential decision to initiate Phase 1b expansion cohorts in specific EGFR positive tumor types in conjunction with partner Amgen (AMGN). BMO expects the stock to react positively “given current levels” to the announcement. It has a Market Perform rating on CytomX with a $3.25 price target. The stock in premarket trading is up 93% to $3.15
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024
- CytomX Therapeutics upgraded to Neutral from Underweight at JPMorgan
- CytomX Therapeutics doses first patient in CX-2051 Phase 1 study
- CytomX announces $5M milestone triggered in Astellas Pharma TCB collaboration
- CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas